Atea Pharmaceuticals (AVIR)

• Market cap: $420M
• 1 day: 5.21%
• 5 days: 10.99%
• 1 month: 7.58%
• 3 months: -5.23%
• 6 months: 26.81%
• Year to date: 50.86%
• 1 year: 51.73%
• 5 years: -83.73%
• 10 years: -82.7%
• Sector: Healthcare
• Industry: Biotechnology

About: Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Employees: 55